Pasadena Site And Tech Integration Will Unlock Future Opportunities

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

24 Sep 24

Updated

27 Feb 26

Views

156

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-17.4%

7D

-3.9%

Loading

1Y

-17.4%

7D

-3.9%

You can edit this narrative until Feb 28 4:35 AM. Then, changes will post as Updates.

Author's Valuation

US$7537.4% undervalued

AnalystConsensusTarget Fair Value

Shared on 27 Feb 26

SCL: Higher Future P/E Assumptions Will Support Long-Term Dividend Upside

Analysts have adjusted their Stepan price target to $75.00, with the change tied to updated views on discount rate, revenue growth, profit margin, and a higher assumed future P/E multiple. What's in the News Stepan Company reported an unaudited goodwill impairment of $6,245,000 for the three months ended December 31, 2025.

1 view

Shared on 11 Feb 26

SCL: Refined Discount Rate Assumptions Will Support Long-Term Dividend Upside

Analysts have kept their Stepan price target steady at $75.00, citing only slight tweaks to assumptions like discount rate, revenue growth, profit margin, and future P/E that were not material enough to change their overall valuation view. Valuation Changes Fair Value: Steady at $75.00, indicating no change in the analysts' central valuation estimate.

0 views

Shared on 27 Jan 26

Fair value Decreased 8.77%

SCL: Higher Discount Rate Will Set Up Attractive Long-Term Dividend Returns

Analysts now estimate Stepan's fair value at US$75.00, reduced from US$82.21. This change reflects updated assumptions regarding a higher discount rate, revised profit margin expectations, a slightly higher revenue growth outlook, and a lower future P/E multiple.

1 view

Shared on 30 Apr 25

Fair value Increased 2.58%

AnalystConsensusTarget has increased profit margin from 5.1% to 5.6%.

2 views

Shared on 23 Apr 25

Fair value Decreased 4.69%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.0%.

0 views

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

0 views

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

0 views

Shared on 02 Apr 25

Fair value Increased 1.58%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

0 views

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

0 views

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

0 views

Shared on 11 Mar 25

Fair value Decreased 2.62%

AnalystConsensusTarget has decreased profit margin from 7.3% to 5.1% and increased future PE multiple from 13.7x to 18.0x.

0 views

Valuator

Company Info

Notes

AnalystConsensusTarget Fair Value

US$75

37.4% undervalued

Future estimation in

Revenue

Profit Margin

Future PE

Growth p.a.

%

Decrease

Increase

Forecast revenue growth rate

4.04%

Historical revenue growth rate

0.44%

Chemicals revenue growth rate

0.36%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

8.53%

Calculation

US$97.90m

Earnings '29

x

22.49x

PE Ratio '29

=

US$2.20b

Market Cap '29

US$2.20b

Market Cap '29

/

23.80m

No. shares '29

=

US$92.51

Share Price '29

US$92.51 Share Price '29

Discounted to 2026 @ 8.48% p.a.

=

US$72.48

Fair Value '26